Rhythm Pharmaceuticals (RYTM) announced that the FDA has accepted for filing the company’s supplemental new drug application for setmelanotide seeking approval for the treatment of conditions associated with acquired hypothalamic obesity. The FDA has granted Priority Review of the sNDA and assigned a Prescription Drug User Fee Act goal date of December 20. Additionally, the European Medicines Agency has confirmed validation of the Type II variation submission to the Marketing Authorization Application for setmelanotide for the same indication. The application review began on August 16 by the Committee for Medicinal Products for Human Use, which will issue an opinion to the European Commission regarding potential approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
- Rhythm Pharmaceuticals’ RM-718 Study: A Potential Game-Changer in Obesity Treatment
- 3 Best Stocks to Buy Now, 8/8/2025, According to Top Analysts
- Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright